JP2013528376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528376A5 JP2013528376A5 JP2013510342A JP2013510342A JP2013528376A5 JP 2013528376 A5 JP2013528376 A5 JP 2013528376A5 JP 2013510342 A JP2013510342 A JP 2013510342A JP 2013510342 A JP2013510342 A JP 2013510342A JP 2013528376 A5 JP2013528376 A5 JP 2013528376A5
- Authority
- JP
- Japan
- Prior art keywords
- odc
- ornithine decarboxylase
- polyamine
- inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 60
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 60
- 239000003112 inhibitor Substances 0.000 claims 30
- 229920000768 polyamine Polymers 0.000 claims 27
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 12
- 235000005911 diet Nutrition 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 10
- 230000000378 dietary effect Effects 0.000 claims 8
- 201000009030 Carcinoma Diseases 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 229940063673 spermidine Drugs 0.000 claims 6
- 229940063675 spermine Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000002271 resection Methods 0.000 claims 4
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 4
- 229960000894 sulindac Drugs 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 3
- 238000011156 evaluation Methods 0.000 claims 3
- 108020002494 acetyltransferase Proteins 0.000 claims 2
- 102000005421 acetyltransferase Human genes 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 230000004941 influx Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical group NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 101150010646 ODC1 gene Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000005700 Putrescine Substances 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- OYYYKBDTBANKSJ-UHFFFAOYSA-N n-(4-aminobutyl)-n-(3-aminopropyl)acetamide Chemical compound NCCCN(C(=O)C)CCCCN OYYYKBDTBANKSJ-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000008261 skin carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical group NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34504810P | 2010-05-14 | 2010-05-14 | |
| US61/345,048 | 2010-05-14 | ||
| PCT/US2011/036464 WO2011143579A2 (en) | 2010-05-14 | 2011-05-13 | Cancer prevention and treatment methods based on dietary polyamine content |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138684A Division JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528376A JP2013528376A (ja) | 2013-07-11 |
| JP2013528376A5 true JP2013528376A5 (enExample) | 2014-07-03 |
| JP6083646B2 JP6083646B2 (ja) | 2017-02-22 |
Family
ID=44915003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510342A Expired - Fee Related JP6083646B2 (ja) | 2010-05-14 | 2011-05-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| JP2016138684A Pending JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016138684A Pending JP2016224056A (ja) | 2010-05-14 | 2016-07-13 | 食事性ポリアミン含量に基づく癌予防及び治療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130217743A1 (enExample) |
| EP (1) | EP2568978B1 (enExample) |
| JP (2) | JP6083646B2 (enExample) |
| CA (1) | CA2799431A1 (enExample) |
| WO (1) | WO2011143579A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| LT2912193T (lt) | 2012-10-29 | 2018-12-27 | Arizona Board Of Regents On Behalf Of University Of Arizona | Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi |
| WO2015195120A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| US12042477B2 (en) | 2016-02-23 | 2024-07-23 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| JP2023528930A (ja) | 2020-06-04 | 2023-07-06 | フェス・セラピューティクス，インコーポレーテッド | がんを処置する個別化された方法 |
| WO2023081612A1 (en) * | 2021-11-02 | 2023-05-11 | Cancer Prevention Pharmaceuticals, Inc. | Methods of treating patients having type 1 diabetes with eflornithine |
| EP4618967A1 (en) * | 2022-11-20 | 2025-09-24 | Universität Zürich | Combination of polyamine pathway inhibitor drug and proline/arginine diet restriction |
| CN115976243A (zh) * | 2023-02-27 | 2023-04-18 | 贵州医科大学 | 口服阿司匹林及阿托伐他汀出现的肠道菌群标志物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2706255B1 (fr) * | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| EP1067919A1 (en) | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo and sulindac combination in cancer chemoprevention |
| JP2004506683A (ja) * | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する |
| PT2430452E (pt) * | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
-
2011
- 2011-05-13 CA CA 2799431 patent/CA2799431A1/en not_active Abandoned
- 2011-05-13 EP EP11781359.2A patent/EP2568978B1/en not_active Not-in-force
- 2011-05-13 JP JP2013510342A patent/JP6083646B2/ja not_active Expired - Fee Related
- 2011-05-13 US US13/697,984 patent/US20130217743A1/en not_active Abandoned
- 2011-05-13 WO PCT/US2011/036464 patent/WO2011143579A2/en not_active Ceased
-
2016
- 2016-07-13 JP JP2016138684A patent/JP2016224056A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528376A5 (enExample) | ||
| Li et al. | Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance | |
| Tschoep-Lechner et al. | Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer | |
| Hoffe et al. | Cancer and age: general considerations | |
| JP2016224056A5 (enExample) | ||
| Meng et al. | Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence | |
| BR112012022801B8 (pt) | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer | |
| Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
| Murphy et al. | Inhibition of the renin–angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia | |
| He et al. | Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder | |
| JP2012526852A5 (enExample) | ||
| Katz et al. | Epigenetic reprogramming in breast cancer: from new targets to new therapies | |
| BR112015002706A8 (pt) | Niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| Men et al. | Nogo‐B: A potential indicator for hepatic cirrhosis and regulator in hepatic stellate cell activation | |
| Yu et al. | Si‐jun‐zi decoction treatment promotes the restoration of intestinal function after obstruction by regulating intestinal homeostasis | |
| Capalbo et al. | Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report | |
| Zylstra et al. | Peri-operative patient optimization for oesophageal cancer surgery–From prehabilitation to enhanced recover | |
| Moreno et al. | Preclinical evaluation of combined targeted approaches in malignant rhabdoid tumors | |
| Wong et al. | New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine‐Refractory Advanced Papillary Thyroid Carcinoma: Literature Review | |
| Pilgrim et al. | The developing clinical problem of chemotherapy‐induced hepatic injury | |
| Welsh et al. | Urticarial vasculitis secondary to paroxetine | |
| Rogers et al. | A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial | |
| Skorupski et al. | Phase I/II clinical trial of 2‐difluoromethyl‐ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma | |
| Lee et al. | Impact of bariatric surgery on the management of type 2 diabetes mellitus in Singapore | |
| Maingon et al. | New challenge of developing combined radio-drug therapy |